Pharmacists describe their experiences using DEA certificates for controlled substance prescribing in different practice settings, as well as barriers and opportunities for future expansion.
|Articles|May 1, 2004
- Volume 0 0
Insomnia Information Is Available
Advertisement
The National Sleep Foundation's Web site (www.sleepfoundation.org) has a new insomnia feature?"Can't Sleep?" The Web site addresses the following topics:
- What Is Insomnia?
- Who Has Insomnia?
- Types of Insomnia
- Available Treatments for Insomnia
- Good Sleep Practices to Manage Insomnia
Insomnia affects >70 million Americans and costs >$14 billion annually in health care costs and an estimated $28 billion in indirect costs, according to figures released by the foundation.
Articles in this issue
over 22 years ago
Aging Brings Changesover 22 years ago
RxPRODUCT NEWS PROFILE: Cubicinover 22 years ago
Can You Read These Rxs?over 22 years ago
Treatment of Sexually Transmitted Diseasesover 22 years ago
Pharmacist Misappropriates Trade Secretsover 22 years ago
Topiramate May Reduce Frequency and Severity of Migraine Headachesover 22 years ago
HRT Is Linked to Breast Cancer Relapseover 22 years ago
Psoriasis May Be Treated Safely and Effectively with AdalimumabAdvertisement
Related to this article
Professional membership and experienced mentor leadership offer new pharmacy technicians a dual advantage, serving as a comprehensive training accelerator.
A biologic stewardship framework can enhance consistency, safety, and sustainability of biologic use in health systems.
Artificial intelligence (AI) transforms a chaotic, reactive process into an adaptive, proactive system that improves workflow and patient safety.
Pharmacists are well equipped to manage DOAC therapy by providing initial education, adherence support, and safety monitoring.
Pharmacists play a key role in guiding age- and risk-based vaccination decisions to protect against invasive and noninvasive disease.
Peer Reviewed
Gepotidacin and zoliflodacin show comparable efficacy to standard care for urogenital gonorrhea, offering promising alternatives given the recent rise in antimicrobial resistance.
With nearly 8 in 10 older adults misusing at least 1 OTC product, clearer counseling and labels could close the gap.
Advertisement
Advertisement
Trending on Pharmacy Times
1
New Bladder Cancer Regimens Reshape Treatment Across Disease Stages
2
FDA Approves Levacetylleucine to Treat Ataxia in Adult, Pediatric Patients With A-T
3
Radioligand Therapy Doesn’t Need to Be Risk-Free—It Needs to Be Worth It
4
FDA Approves Rebisufligene Etisparvovec as First Gene Therapy for Children With Sanfilippo Syndrome Type A
5